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Abstract 
Background: Chromosomal microarray offers superior sensitivity for identification of submicroscopic copy number 
variants (CNV) and it is advocated to be the first tier genetic testing for patients with autism spectrum disorder (ASD). 
In this regard, diagnostic yield of array comparative genomic hybridization (CGH) for ASD patients is determined in a 
cohort of Chinese patients in Hong Kong.
Methods: A combined adult and paediatric cohort of 68 Chinese ASD patients (41 patients in adult group and 27 
patients in paediatric group). The genomic DNA extracted from blood samples were analysed by array CGH using 
NimbleGen CGX‑135K oligonucleotide array.
Results: We identified 15 CNV and eight of them were clinically significant. The overall diagnostic yield was 11.8 %. 
Five clinically significant CNV were detected in the adult group and three were in the paediatric group, providing 
diagnostic yields of 12.2 and 11.1 % respectively. The most frequently detected CNV was 16p13.11 duplications which 
were present in 4 patients (5.9 % of the cohort).
Conclusions: In this study, a satisfactory diagnostic yield of array CGH was demonstrated in a Chinese ASD patient 
cohort which supported the clinical usefulness of array CGH as the first line testing of ASD in Hong Kong.
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Background
Autism spectrum disorder (ASD) is a collective term 
describing a range of neurodevelopmental disorders with 
core features of deficits in communications and social 
interactions, accompanied by stereotyped behaviours and 
restricted interest. The global prevalence was reported to 
be 1 in 161 children, affecting more males than females 
[1]. Being regarded as a crucial factor for the aetiology of 
ASD, genetic alterations identified in affected patients are 
remarkably heterogeneous across the whole genome [2].
Evidently, a number of chromosomal abnormali-
ties have been recognised to be associated with ASD 
phenotype [3]. Nevertheless, the diagnostic yield of 
conventional G-banded karyotype has been  reported 
to be only 3  % [4]. Notably, chromosomal microarray 
(CMA) is regarded as a robust and comprehensive tool 
for genome-wide detection of submicroscopic deletions 
and duplications, which are named as copy number 
variants (CNV). The advantage of high resolution using 
CMA translates into major improvement in the detection 
rate. Indeed, the implications of rare CNV on the patho-
genesis of ASD have been increasingly acknowledged [5]. 
CMA is now regarded as the first tier genetic testing for 
ASD patients [6]. The diagnostic importance of CMA for 
ASD has been demonstrated in diverse clinical settings 
[7–9]. Overall, the frequency of finding clinically signifi-
cant CNV in ASD patients has been shown to be approx-
imately 7–9 % [10, 11]. Moreover, Tammimies et al. has 
demonstrated that the diagnostic yield was significantly 
higher in those with more complex morphological phe-
notype [12]. Nevertheless, in majority of the CNV studies 
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in ASD, the subjects are predominately from Caucasian 
ancestry. Seemingly, genomic data in other population is 
crucial, especially when CMA are increasingly adopted in 
clinical laboratories.
In this study, we determined the clinical usefulness of 
CMA in evaluation of ASD patients in our population. 
Array comparative genomic hybridization (CGH) is the 
platform that used for identification of CNV in a Chinese 
ASD patient cohort from Hong Kong. We present here 
the diagnostic yield of this investigative tool in a com-
bined adult and paediatric cohort.
Methods
Patients
We evaluated a combined adult and paediatric cohort 
of 68 patients (60 males and 8 females). All the patients 
are unrelated. The adult patients were recruited from 
a cohort of a local study on the adult outcome of chil-
dren with autism with normal intelligence [13]. Forty-
one patients were in the adult group (39 males and 2 
females) and the age was 22–33 years (median 27 years). 
This group consisted of ASD patients who were diag-
nosed in childhood by psychiatrists, paediatricians or 
clinical psychologists before year 1990, using the Diag-
nostic and Statistical Manual of Mental Disorders, Third 
Revised Edition, and confirmed with the development, 
dimensional and diagnostic interview [14] during adult-
hood in the aforementioned study. The adult cohort was 
also assessed with Wechsler Adult Intelligence Scale-
Third Edition (WAIS-III) Chinese version [15] and con-
firmed to have normal intelligence with full IQ score of 
75 or above. They had follow-up in clinic under Kwai 
Chung Hospital. In the paediatric group, 27 patients were 
recruited (21 males and 6 females), aged 2–15 (median 
5  years). The paediatric patients were assessed in the 
Department of Paediatrics and Adolescent Medicine of 
Princess Margaret Hospital or Tuen Mun Hospital. The 
paediatric patients were assessed using autism diagnostic 
interview-revised (ADI-R) [16] to confirm the diagnosis 
of ASD. Thirteen patients in the paediatric group (52.0 %) 
also had developmental delay. The study was approved 
by the Clinical Research Ethic Committee of Kowloon 
West Cluster & New Territories West Cluster of Hospi-
tal Authority (Reference number: KWC/FR/10-007 and 
NTWC/CREC/1004/11). Informed consent was obtained 
from all parents or patients.
Array CGH and data interpretation
Peripheral blood samples were collected in EDTA tubes 
for genomic DNA extraction using QIAamp Blood Kit 
(Qiagen, Hilden, Germany). The quantity of DNA in the 
samples was measured by Nanodrop spectrophotom-
eter and all samples had an A260/A280 ratio more than 
or equal to 1.8. Agarose gel electrophoresis was used for 
the assessment of DNA quality to preclude any degra-
dation or RNA contamination. NimbleGen CGX-135K 
oligonucleotide arrays [Genome Build: hg18] were used 
in this study and the method was previously described 
[17]. This platform had been used in multiple clinical 
microarray studies [18–21]. The data was analysed using 
DEVA (Roche NimbleGen, Wisconsin, USA) and Geno-
glyphix (Signature Genomics, Spokane, USA). The qual-
ity of array CGH experiments has been assessed through 
the parameters in the quality metric report. The reports 
include “signal range” and “ratio range” which represent 
the uniformity of log-2 ratio over the array. The lower the 
value, the better the quality of the data. The array CGH 
data of all samples had “signal range” and “ratio range” 
below the cutoffs suggested by the manufacture which 
were <1.0 and <1.5 respectively.
The clinical significance of the CNV detected was deter-
mined using the information available in the open access 
databases including Database of Chromosomal Imbal-
ance and Phenotype in Human using Ensembl Resources 
(DECIPHER), Database of Genomic Variant (DGV), 
International Standards for Cytogenomic Arrays Consor-
tium Database (ISCA), and Simons Foundation Autism 
Research Initiative Gene (SFARI Gene). Categorization 
of CNV is based on available information on the clinical 
significance of genes in the region of deletions or duplica-
tions via the search in The University of California Santa 
Cruz (UCSC) Genome Browser, Pubmed and Online 
Mendelian Inheritance in Man (OMIM). CNV are clas-
sified into pathogenic, uncertain clinical significance and 
benign based on American College of Medical Genetics 
guideline [22] and the pathogenic and likely pathogenic 
CNV are deemed to be clinically significant. Detection 
rate was defined as the number of patients with CNV 
divided by the total number of patients tested and diag-
nostic yield was determined as the percentage of patients 
with clinically significant CNV among patients tested.
Results
Table 1 shows the summary of the patient characteristics 
and CNV findings. We identified 15 CNV in the cohort 
68 ASD patients, giving CNV detection rate of 22.1  %. 
Among patients with CNV, there were 13 males and two 
females. The CNV detection rates in male and female 
patients were 21.7 and 25  % respectively. In the adult 
group, CNV were detected in 8 male patients. The over-
all CNV detection rate in the adult group was 19.5 % for 
all adults and 20.5 % for male adults. Seven patients with 
CNV were from the paediatric group with five males and 
two female. The overall CNV detection rate in the pae-
diatric group was 25.9 % (23.8 % for male and 33.3 % for 
female).
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Among the detected CNV, eight of them were classi-
fied as clinically significant, which gives an overall diag-
nostic yield of 11.8 %. Five was from the adult group and 
three was the paediatric group and the diagnostic yield 
was 12.2 and 11.1 % respectively. All patients with clini-
cally significant CNV in the adult group were male. In 
the paediatric group, the clinically significant CNV were 
found in one male and two female patients. Variants of 
uncertain clinical significance (VOUS) were detected in 
seven patients, which contributed to 10.3 % of the entire 
cohort. The detected CNV were compared to the pub-
lished CNV map of the human genome [23]. The array 
CGH data was shown in Additional file 1: Figure S1–S12.
The eight clinically significant CNV contributed to 
53.3  % of all CNV (8 out of 15 CNV) detected. Four of 
them were deletions and another four are duplications. 
The largest clinically significant CNV identified sized 
14.53 Mb while the smallest was 0.12 Mb. Seven of them 
were below 5 Mb (87.5 %) which was the size range not 
routinely detectable by karyotype. The size of five CNV 
was between 1 and 5 Mb (62.5 %) and two were <1 Mb 
(25.0 %).
The clinically significant CNV were listed in Table  2. 
Among the clinically significant CNV, 1.16 Mb microdu-
plications within chromosome band 16p13.11 were most 
frequently observed and these were detected in three adult 
patients and one paediatric patient. In the adult group, 
one patient had 1.97  Mb microdeletion at 15q23–q24.1 
encompassing 19 genes. Another had 0.26  Mb micro-
deletion within chromosome band 15q11.2 overlapping 
Prader-Willi/Angelman region and involving NIPA1 gene. 
In the paediatric group, one patient had a large  terminal 
deletion of chromosome 18 from band q22.1 to q23 which 
is 14.53 Mb in size. Another paediatric patient had 14q22.1 
microdeletion involving the whole NIN gene.
For the seven VOUS, six were duplications and one 
was deletion. All of them were less than 5 Mb. The size of 
VOUS ranged from 0.08 to 0.97 Mb. The VOUS are listed 
in Table 3.
Discussion
We identified 11.8  % patients with clinically significant 
CNV in our ASD cohort by array CGH. The diagnostic 
yield in this study was in keeping with other studies [11, 
24]. If conventional G-banded karyotype was used as 
the first line test, only one patient in our cohort (1.5 %) 
would have chromosomal abnormality detected micro-
scopically. With high resolution, array CGH is capable of 
identifying the underlying chromosomal cause of ASD in 
a much greater number of patients. Evidently, our results 
demonstrated a satisfactory diagnostic yield of array 
CGH for genetic diagnosis in ASD patients, confirm-
ing its clinical usefulness as first  tier testing. The diag-
nostic yield of the in the adult and paediatric group was 
comparable.
In addition, array CGH also allowed better delineation 
of the breakpoints of the CNV. The improved accuracy 
facilitated genotype-phenotype correlation and identifi-
cation of candidate genes [6]. In the patient with 15q11.2 
deletion at Prader-Willi/Angelman region, the dele-
tion overlapped with reported microdeletion at 15q11.2 
between breakpoint (BP) 1 to 2 which was a susceptibility 
region for autism and language delay [25, 26]. The phe-
notype of this BP1–BP2 microdeletion is different from 
those with deletions with proximal breakpoint at BP1 or 
BP2 and distal breakpoint at BP3 which result in classi-
cal Prader-Willi/Angelman syndrome. In the patient with 
deletion at 15q23–q24.1, the deletion overlapped with 
previously reported 15q24 deletion in ASD patients [27, 
28]. The improved breakpoint delineation drove the iden-
tification of novel disease gene NEO1 which conferred 
aetiological importance in ASD [29].
The largest CNV detected in this cohort was a deletion 
within chromosome band 18q21.1q23. The deletion, arr 
18q22.1q23 (61,576,686–76,114,624) × 1, encompassed a 
minimum size of 14.53 Mb and involved 38 genes from 
CDH7 to PARD6G (Additional file 1: Figure S13). Dele-
tions of 18q were deemed to be a particularly heteroge-
neous genomic disorder as no recurrent breakpoints 
were identified [30]. With remarkable genomic hetero-
geneity, the phenotypes of patients with 18q deletion 
Table 1 Summary of patient characteristics and CNV find-
ings
N/A not available
Overall Adult group Paediatric group
Number of patients 68 41 27
 Male 60 39 21
 Female 8 2 6
Age range (median) [years] 2–33 (25) 22–33 (27) 2–15 (5)
Intelligence quotient 
(median)
N/A 75–129 (96) N/A
Total number of CNV 15 8 7
(Detection rate  %) (22.1) (19.5) (25.9)
 Detected in male 13 8 4
 (Detection rate  %) (21.7) (20.5) (19.0)
 Detected in female 2 0 3
 (Detection rate  %) (25) (0) (50)
Clinical significant CNV 8 5 3
(Diagnostic yield  %) (11.8) (12.2) (11.1)
 Detected in male 6 5 1
 (Diagnostic yield  %) (10) (12.8) (4.8)
 Detected in female 2 0 2
 (Diagnostic yield  %) (25) (0) (33.3)
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were highly variable. Thus, it was not feasible to derive 
this condition based on a collection of clinical character-
istics, and genomic analysis would be indispensable for 
the diagnosis. Clinically, our patient had developmental 
delay, hypotonia, hearing loss, delayed myelination of 
the brain, umbilical hernia and ear canal stenosis which 
were deemed to be core features of distal 18q deletion 
[31]. In addition, congenital cardiac anomalies were also 
one of clinical characteristics of 18q deletion that were 
present in up to 54 % patients [31–33]. For our patient, 
the echocardiogram was normal. Particularly, constitu-
tional hemizygosity of 18q has been reported to confer 
increased risk of autism. Forty-three percent of patients 
with 18q deletion were categorised to be at risk of autism 
and the likelihood was significantly increased when 
TCF4, NETO1 and FBXO15 were included in the region 
of hemizygosity [34]. In our patient, NETO1 and FBXO15 
were included in the deletion. Nevertheless, no shared 
region of deletion has been identified among the autistic 
patients with 18q deletion. Hence, the genetic determi-
nants of autism in this group of patients were yet to be 
elucidated.
The 16p13.11 duplications were the most frequent 
clinically significant CNV identified in our cohort. Four 
patients carried the 16p13.11 duplications and all of 
them shared the same breakpoints at position 15.03 to 
16.20 Mb. This represented 5.9 % of our ASD cohort. The 
main mechanism underpinning the recurrent duplica-
tions and deletions at 16p13.11 is the non-allelic homolo-
gous recombination occurring between low copy repeats. 
The recurrent 16p13.11  duplications have established 
association with autism [35, 36] and a wide range of neu-
ropsychiatric disorders including schizophrenia [37], 
attention-deficit hyperactivity disorder [38], and intellec-
tual disability [39]. Inheritance from unaffected or mildly 
affected parents has been reported for the 16p13.11 
duplications, indicating incomplete penetrance [35, 36].
Indeed, the effect of 16p13.11 duplications is not 
without controversy as its frequency in normal popula-
tion is >1 % and thus being regarded as a common CNV. 
These duplications have been considered to be benign or 
uncertain significance in certain studies [40, 41]. Never-
theless, two large surveys on case–control cohorts, with 
case numbers of 10,397 and 29,085 respectively, have 
consistently demonstrated 16p13.11 duplications predis-
posing to ASD and other kinds of neurodevelopmental 
disorders with statistically significant odd ratios [42, 43]. 
In the earlier study for one of the aforementioned sur-
vey, the odd ratio did not reach the statistical significance 
with the case number of 15,767 [44]. This illustrates that 
a remarkably large sample size is required to demonstrate 
the effect of these alleles with reduced penetrance. It has 
been recognised that common variations are account-
able for majority of the genetic risk for ASD [45]. Seem-
ingly, this susceptibility allele has an indisputable role in 
the genetic architecture of autism [43]. For interpreta-
tion in individual patients, prudent judgment should be 
exercised for the evaluation of the CNV with reduced 
penetrance and complete interpretation should be made 
in the context of phenotypic evaluation and establishing 
inheritance pattern.
Interestingly, the detection rate of 16p13.11 duplica-
tions was relatively high in this study comparing to other 
CNV studies of ASD. Although CNV data in population-
matched controls was not available in the study, the CNV 
map of the human genome showed that 16p13.11 dupli-
cations were not particularly prevalent in Asian compar-
ing to the other ethnic group [23]. Furthermore, the high 
proportion of duplications detected might be related the 
clinical characteristics of the adult cohort which they 
had severe impairment related to autistic symptoms but 
normal intelligence. It has been reported that duplica-
tions correlated to autism severity while deletions had 
impact on nonverbal IQ [46]. This might explain why of 
Table 3 List of variants of uncertain significance
N/A not available
Patient 
number
Gender/group Array CGH result [hg18] Chromosome 
region
Aberration 
type
Size 
(Mb)
IQ Additional  
clinical features
9 Male/adult arr 3q13.3 (111,747,166–112,297,084) × 3 3q13.3 Duplication 0.55 96 Nil
10 Male/adult arr 1q44 (244,474,644–245,087,421) × 3 1q44 Duplication 0.61 85 Nil
11 Female/adult arr 11q24.1 (122,330,312–122,406,276) × 3 11q24.1 Duplication 0.08 103 Nil
12 Female/ 
paediatric
arr 10p12.33p12.32 (19,502,326–
20,471,711) × 3
10p12.33–
p12.32
Duplication 0.97 N/A Scoliosis
13 Male/paediatric arr 17q21.33 (45,861,307–45,986,282) × 3 17q21.33 Duplication 0.12 N/A Developmental delay
14 Male/paediatric arr 6q14.1 (82,900,869–83,543,710) × 3 6q14.1 Duplication 0.64 N/A Developmental delay/regres‑
sion, asthma, severe eczema
15 Male/paediatric arr 5q33.1 (148,226,533–148,809,596) × 1 5q33.1 Deletion 0.58 N/A Nil
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duplications were dominated in the adult cohort of this 
study. In addition, due to the uncertainty of the effect of 
16p13.11 duplications, the possibility of underreport-
ing of this CNV in other autism studies could not be 
excluded.
One patient had a deletion at chromosome 14q22.1 
involving the NIN gene. Compound heterozygous muta-
tions of NIN gene were reported in microcephalic pri-
mordial dwarfism disorder [47]. We sequenced all the 
coding exons and flanking regions of NIN gene but did 
not reveal any other pathogenic mutations (data not 
shown). Clinically, the patient had normal growth and 
no dysmorphic features. NIN gene encoded for ninein, a 
centrosomal protein involved in microtubule anchoring. 
In the absence of ninein, the progenitors were prema-
turely depleted at the ventricular zone of the develop-
ing mammalian neocortex [48]. Having played a crucial 
role on microtubule stability, ninein had significant 
impact on the axonal development and bifurcation [49]. 
Disruptions of neocortex development and axon guid-
ance were proven to be pivotal in the pathophysiol-
ogy of ASD [50–53]. Those findings on the function of 
ninein in brain development indicated the possible link 
between NIN gene and autism. As exemplified by CNT-
NAP2 and NRXN1 gene, heterozygous missense variants 
confer susceptibility to autism [54, 55] while compound 
heterozygous mutations of CNTNAP2 and NRXN1 cause 
Pitts-Hopkins like syndrome [56]. Moreover, deletion in 
this region has not been reported in any normal subjects 
from the DGV database. Therefore, we classified this 
deletion as clinically significant and NIN gene might be 
considered to be a potential candidate gene for ASD.
This study demonstrated the spectrum of CNV in Chi-
nese ASD patients from Hong Kong and they showed dif-
ferences in certain aspects comparing with the CNV data 
from other studies which were mainly from European 
ancestry [5, 12, 40, 46]. Similar to the other studies, the 
CNV detected were majority on the hotspots with recur-
rent breakpoints but the proportion was higher in this 
study. The CNV in hotspot with recurrent breakpoints 
generally accounted for 37–53 % of CNV detected in the 
ASD patients in previous studies [12, 40] and the propor-
tion was 62.5  % (5 out of 8 clinically significant CNV) 
in this cohort. Moreover, CNV in 16p11.2 was demon-
strated to be the most commonly detected CNV in ASD 
patients but it was still found in largely below 1 % of ASD 
subjects [12, 27, 40, 46]. In contrast, the most frequently 
detected CNV in this cohort was 16p13.11 duplications, 
which were present in 5.9  % of ASD patients. The rea-
son underpinning such a high detection rate has not yet 
been fully elucidated but this should be validated in a 
larger Chinese cohort and compared with controls from 
the local population. The yield of highly penetrant CNV 
was also relatively low in this study. This could be related 
to the clinical characteristics of this cohort. From the 
review of medical record, most of the patients did not 
have additional clinical features apart from autism. The 
presence of other physical anomalies has been shown to 
result in higher diagnostic yield [12]. Furthermore, there 
was CNV disrupting genes that had not yet described to 
be linked to ASD. This concurred with other evidence 
showing numerous genes associated with ASD scattered 
across the genome and many of ASD risk genes remained 
to be identified.
In this study, VOUS accounted for 46.7  % of all CNV 
detected (7 out of 15 CNV). All VOUS were less than 
1  Mb in size and majority of them were duplications. 
Parental results might facilitate the interpretation of the 
VOUS but the parental samples were not available dur-
ing the recruitment which represented a limitation of 
this study. Yet, inheritance from parents would not com-
pletely diminish the clinical significance of variants with 
incomplete penetrance, like the 16p13.11 duplications. 
In addition, the small size of the duplications would not 
entirely preclude pathogenic effects. Indeed, evidence 
for dosage pathogenicity of genes in those regions would 
be a more important factor to be considered. To exem-
plify, duplication of a single gene could result in severe 
phenotype like in MECP2 duplication syndrome which 
was associated with autism and mental retardation [57]. 
Therefore, these VOUS might still deserve further inves-
tigations for any possible association with ASD.
It was acknowledged that limitation existed in this 
study. In terms of number of patients, it was relatively 
small in this cohort. The retrospective cohort study 
design also made it prone to selection bias. Moreover, 
this retrospective cohort of patients with confirmed 
diagnosis of ASD did not have systematic phenotypic 
documentation in details. Thus, this restricted the estab-
lishment of genotype and phenotype correlation and 
stratification of the diagnostic yield in patients according 
to additional clinical features. Another deficiency of this 
study is the absence of parental samples which could be 
helpful for the determination of the inheritance to aid the 
interpretation particularly for VOUS. In addition, control 
CNV data from normal individuals in the same popula-
tion were lacking in the present study. The findings from 
this study should be validated in a larger Chinese ASD 
cohort from Hong Kong with CNV data from popula-
tion-matched controls for interpretation. On the ana-
lytical aspect, the CNV findings were not checked with 
a second method. However, all the raw data of each CNV 
was manually inspected and passed the recommended 
quality parameters.
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Conclusions
Our study demonstrated a satisfactory diagnostic yield 
of array CGH in a Chinese ASD patient cohort. Having 
high resolution for CNV detection, array CGH made a 
sizeable difference to delineate the genomic alterations in 
ASD patients. Seemingly, the results supported the clini-
cal usefulness of array CGH as the first tier test of ASD in 
Hong Kong.
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